{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
Lutime by SAMSON PHARMACEUTICAL
(2018)
Source URL:
First approved in 2018
Source:
Lutime by SAMSON PHARMACEUTICAL
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(1985)
Source URL:
First approved in 1985
Source:
21 CFR 348
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT01625442: Phase 4 Interventional Completed Metabolic Syndrome
(2010)
Source URL:
Class:
STRUCTURALLY DIVERSE